A Randomized, Double-blind, Phase 1/2a Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.preF in Adults 18 to 50 Years of Age, RSV-seropositive Toddlers 12 to 24 Months of Age
Phase of Trial: Phase I/II
Latest Information Update: 05 Mar 2018
At a glance
- Drugs JNJ 64400141 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- Sponsors Janssen Vaccines and Prevention B.V
- 12 Jan 2018 Planned number of patients changed from 48 to 60.
- 04 Dec 2017 Status changed from not yet recruiting to recruiting.
- 13 Nov 2017 Planned End Date changed from 25 Jan 2019 to 29 Mar 2019.